Sales & Marketing News | pharmaphorum

News

Sage considering cuts after FDA setback

Sage Therapeutics is facing the possibility of job losses and other cutbacks in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the

News

Astellas' Iveric takeover rewarded with FDA nod for GA drug

The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company

News

Zuranolone cleared for post-partum depression, but not MDD

Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a requ

News

AZ, Sanofi's Beyfortus gets CDC okay for RSV prevention

The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centre

News

PacBio builds in short-read sequencing with $110m Apton buy

Gene sequencing specialist PacBio has reached an agreement to buy Apton Biosystems, boosting its position in short-read sequencing technology that has traditionally been d

News

GSK takes RSV jab rivalry with Pfizer into the courts

GSK has filed a lawsuit against Pfizer in a US court alleging infringement of patents that it holds on vaccines against respiratory syncytial virus (RSV).

Sage considering cuts after FDA setback

Astellas' Iveric takeover rewarded with FDA nod for GA drug

Zuranolone cleared for post-partum depression, but not MDD

AZ, Sanofi's Beyfortus gets CDC okay for RSV prevention

PacBio builds in short-read sequencing with $110m Apton buy

GSK takes RSV jab rivalry with Pfizer into the courts

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks